Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) on Friday, soared 2.68% from the previous trading day, before settling in for the closing price of $22.76. Within the past 52 weeks, CPRX’s price has moved between $14.47 and $26.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 39.23%. The company achieved an average annual earnings per share of 15.14%. With a float of $111.13 million, this company’s outstanding shares have now reached $121.96 million.
Let’s determine the extent of company efficiency that accounts for 181 employees. In terms of profitability, gross margin is 84.1%, operating margin of 39.68%, and the pretax margin is 43.98%.
Catalyst Pharmaceuticals Inc (CPRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Catalyst Pharmaceuticals Inc is 8.89%, while institutional ownership is 76.75%. The most recent insider transaction that took place on Mar 06 ’25, was worth 3,902,680. In this transaction Chief Med. & Reg. Officer of this company sold 180,096 shares at a rate of $21.67, taking the stock ownership to the 68,873 shares. Before that another transaction happened on Mar 05 ’25, when Company’s Chief Med. & Reg. Officer sold 44,904 for $22.09, making the entire transaction worth $991,929. This insider now owns 68,873 shares in total.
Catalyst Pharmaceuticals Inc (CPRX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 15.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.19% during the next five years compared to 34.27% growth over the previous five years of trading.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Trading Performance Indicators
Catalyst Pharmaceuticals Inc (CPRX) is currently performing well based on its current performance indicators. A quick ratio of 5.96 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.33. Likewise, its price to free cash flow for the trailing twelve months is 10.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.57, a number that is poised to hit 0.40 in the next quarter and is forecasted to reach 1.67 in one year’s time.
Technical Analysis of Catalyst Pharmaceuticals Inc (CPRX)
Looking closely at Catalyst Pharmaceuticals Inc (NASDAQ: CPRX), its last 5-days average volume was 1.53 million, which is a jump from its year-to-date volume of 1.31 million. As of the previous 9 days, the stock’s Stochastic %D was 44.77%. Additionally, its Average True Range was 1.05.
During the past 100 days, Catalyst Pharmaceuticals Inc’s (CPRX) raw stochastic average was set at 60.22%, which indicates a significant decrease from 61.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.76% in the past 14 days, which was lower than the 47.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.00, while its 200-day Moving Average is $21.50. However, in the short run, Catalyst Pharmaceuticals Inc’s stock first resistance to watch stands at $23.75. Second resistance stands at $24.13. The third major resistance level sits at $24.57. If the price goes on to break the first support level at $22.94, it is likely to go to the next support level at $22.50. Now, if the price goes above the second support level, the third support stands at $22.12.
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Key Stats
Market capitalization of the company is 2.85 billion based on 121,959K outstanding shares. Right now, sales total 491,730 K and income totals 163,890 K. The company made 141,820 K in profit during its latest quarter, and 55,940 K in sales during its previous quarter.
